STAT+: FDA approves first personalized cell therapy for patients with multiple myeloma

The Food and Drug Administration on Friday approved the first personalized cell therapy to treat patients with advanced multiple myeloma. It will be marketed under the brand name Abecma by its makers, Bristol Myers Squibb and Bluebird Bio.

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell that helps fight infections. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney damage, bone destruction, and impaired immune function.

Continue to STAT+ to read the full story…

STAT+: FDA approves first personalized cell therapy for patients with multiple myeloma

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top